Why Did QNTM Stock Pop In Pre-Market Today?

• The study will evaluate the drug’s safety, effectiveness, and tolerability, with initiation expected in the second quarter of 2026.
• Lucid-MS is designed to protect nerves by targeting Demyelination, a key factor for multiple sclerosis progression.
• Allucent will provide end-to-end support for the clinical trial, including execution and data management.

Shares of Quantum BioPharma (QNTM) surged 15% in pre-market trading on Monday after the biotech firm signed a binding agreement with Allucent to support a planned Phase 2 trial of its Lucid-MS therapy for multiple sclerosis.

The study will evaluate the drug’s safety, effectiveness, and tolerability, with initiation expected in the second quarter of 2026, Quantum BioPharma said.

Lucid-MS is designed to protect nerves by targeting Demyelination, a key factor for multiple sclerosis progression. Allucent will provide end-to-end support for the clinical trial, including execution and data management.

“This innovative mechanism represents a differentiated therapeutic approach in the global MS market where an estimated 2.8 million people suffer and where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration,” said Andrzej Chruscinski, VP, Scientific and Clinical Affairs at Quantum BioPharma.  

Funding Update

Earlier this month, Quantum BioPharma completed oral dosing of Lucid-21-302 (Lucid-MS) in both its 180-day toxicity and toxicokinetic studies, marking an important step toward filing an Investigational New Drug (IND) application with the U.S. FDA. The company is focused on developing innovative treatments for neurodegenerative, metabolic, and alcohol-related disorders, with multiple drug candidates in its pipeline.

Alongside clinical progress, Quantum BioPharma also strengthened its financial position by closing the first tranche of a previously announced offering, raising $3.75 million through the issuance of 3,750 debenture units. 

Additionally, the company settled about $1.12 million in debt by issuing over 370,000 Class B shares to certain creditors and insiders, helping improve its balance sheet.

How Did Stocktwits Users React?

Retail sentiment for QNTM remained 'bullish' over the past 24 hours, amid 'extremely high' message volumes.

One user said the company's market cap should be "north of $100 million" following the developments.

Year-to-date, the stock has declined 30%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.